Free Trial

DaVita (DVA) Stock Forecast & Price Target

$137.32
-5.18 (-3.64%)
(As of 07/26/2024 ET)

DaVita - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 4 Wall Street analysts who have issued ratings for DaVita in the last 12 months, the stock has a consensus rating of "Hold." Out of the 4 analysts, 3 have given a hold rating, and 1 has given a buy rating for DVA.

Consensus Price Target

$146.00
6.32% Upside
High Forecast$150.00
Average Forecast$146.00
Low Forecast$134.00

According to the 4 analysts' twelve-month price targets for DaVita, the average price target is $146.00. The highest price target for DVA is $150.00, while the lowest price target for DVA is $134.00. The average price target represents a forecasted upside of 6.32% from the current price of $137.32.

TypeCurrent Forecast
7/27/23 to 7/26/24
1 Month Ago
6/27/23 to 6/26/24
3 Months Ago
4/28/23 to 4/27/24
1 Year Ago
7/27/22 to 7/27/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
3 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$146.00$144.67$118.50$98.75
Forecasted Upside6.32% Upside9.67% Upside2.28% Upside13.62% Upside
Get DaVita Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.

DVA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

DaVita Stock vs. The Competition

TypeDaVitaMedical CompaniesS&P 500
Consensus Rating Score
2.25
2.72
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside6.32% Upside2,864.75% Upside9.14% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/24/2024TD Cowen
4 of 5 stars
 Boost TargetHold ➝ Hold$139.00 ➝ $150.00+5.31%
5/15/2024Truist Financial
1 of 5 stars
 Boost TargetHold ➝ Hold$135.00 ➝ $150.00+9.50%
5/6/2024Barclays
2 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$133.00 ➝ $150.00+10.03%
2/14/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$113.00 ➝ $134.00+9.48%
5/15/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$88.00 ➝ $100.00+6.70%
5/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$85.00 ➝ $113.00+10.50%
5/9/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$86.00 ➝ $96.00+7.61%
2/23/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$76.00 ➝ $90.00+5.42%
8/9/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$95.00+4.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:48 AM ET.

DVA Forecast - Frequently Asked Questions

What is DaVita's forecast for 2024?

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for DaVita is $146.00, with a high forecast of $150.00 and a low forecast of $134.00.

Should I buy or sell DaVita stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DaVita in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DVA, but not buy additional shares or sell existing shares.

Does DaVita's stock price have much upside?

According to analysts, DaVita's stock has a predicted upside of 8.52% based on their 12-month stock forecasts.

What analysts cover DaVita?

DaVita has been rated by research analysts at Barclays, TD Cowen, and Truist Financial in the past 90 days.

Do Wall Street analysts like DaVita more than its competitors?

Analysts like DaVita less than other "medical" companies. The consensus rating for DaVita is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DVA compares to other companies.


This page (NYSE:DVA) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners